Tyra Biosciences, Inc.
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
HC Wainwright & Co. kept a Buy rating on Tyra Biosciences (TYRA) with a $29 price target, suggesting a 13.1% upside from the Sep 21 close. The firm highlights Tyra's pipeline and SNAP platform as strengths.
Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TYRA (Tyra Biosciences, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent TYRA coverage spans financial news, technology and corporate actions.
In the last 30 days, TYRA insiders filed 1 SEC Form 4 transaction — 1 purchase ($20K) and no sales. The most active reporter was Verjee Rehan with 1 filing.
Potential slight downside.
Analyst upgrade may lift the stock toward the $29 target.
Positive early efficacy may drive near-term price appreciation and set up Phase 3 momentum.
The capital raise provides significant funding for drug development and working capital.
Large capital raise provides runway for multiple indications and supports near-term price rally.
AlphAI scores every news story that mentions TYRA with an AI model for sentiment and relevance, and aggregates insider trades from Tyra Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
2 min readHC Wainwright & Co. kept a Buy rating on Tyra Biosciences (TYRA) with a $29 price target, suggesting a 13.1% upside from the Sep 21 close. The firm highlights Tyra's pipeline and SNAP platform as strengths.
1 min readTyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.
2 min readTyra priced an offering of 9.08M common shares at $22.03 each and 9.08M pre-funded warrants at $22.029 each, expected to raise $400M. Underwriters bought at $20.7082 per unit. Proceeds will support drug development and corporate purposes, according to the company.
1 min readTyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
3 min readElmet Group (ELMT) shares surged 50.6% to $24.39 after announcing plans to use a $450M DoD investment to boost tungsten supply. Other stocks gaining include Rum Group (RUM) +15%, Tyra Biosciences (TYRA) +14.5%, and Roblox (RBLX) +8.7% after price target raises.
2 min readTyra Biosciences (TYRA) stock rose 9.8% after announcing a $400M public offering at $22.03 per share, with proceeds funding clinical programs. The offering was led by RA Capital and major banks, following positive Phase 2 trial results. The company aims to advance its dabogratinib 3x3 strategy, targeting specific cancers and achondroplasia.
2 min readVerjee Rehan purchased 972 shares of Tyra Biosciences, Inc. (TYRA) at $20.58 on 2026-09-09.
1 min readTyra Biosciences (TYRA) reported positive Phase 2 results for dabogratinib in LG IR NMIBC, showing 79% ORR and 64% CR rate at 60 mg QD. The company plans Phase 3 studies and further evaluation in the ablative setting. Dabogratinib demonstrated favorable safety and tolerability. TYRA stock is down 31.72% in pre-market trading.
2 min readUS equity futures fell as Brent crude oil topped $100, pushing 10-year Treasury yields above 4.81%. Meta (META) rose 5% on strong AI usage, while other Mag 7 stocks traded mixed. Braze (BRZE) dropped 11% on weak earnings forecasts, and ServiceTitan (TTAN) fell 17% on revenue concerns. Chime (CHYM) gained 9% after acquiring Stride Bank. Oil prices surged after US strikes on Iranian tankers, and Treasury Secretary Scott Bessent challenged traders on yen strength. Barclays raised its S&P 500 target
3 min read
